News

Aug. 08. 2018

Upsher-Smith Launches Bexarotene Capsules

Jul. 17. 2018

Upsher-Smith Launches Vigabatrin for Oral Solution Under the Brand Name Vigadrone^™

Jun. 20. 2018

Announcement on Completion of Transfer of Manufacturing and Marketing Approval of Zomig^® Tablets 2.5 mg and Zomig^® RM Tablets 2.5 mg, Migraine Treatment

Jun. 14. 2018

Sawai Pharmaceutical Launches 7 Compounds with 17 Strengths of Generic Drugs

Jun. 06. 2018

MHLW approves New Indication for OSELTAMIVIR Capsules 75 mg [SAWAI] / Dry Syrup 3% [SAWAI]

May. 25. 2018

Sawai Pharmaceutical Submits Public Knowledge-Based Application for Anti-Cancer Agent OXALIPLATIN I.V. Infusion Solution for Additional Indication

May. 15. 2018

Announcement on Personnel Changes

May. 10. 2018

Upsher-Smith Launches Doxazosin Tablets, USP

Apr. 04. 2018

MHLW approves New Indication for OLANZAPINE formulation and New Administration for MEROPENEM formulation

Mar. 26. 2018

Announcement on Organizational Changes and Personnel Changes

Mar. 20. 2018

MHLW approves New Indication for PRAMIPEXOLE HYDROCHLORIDE Tablets 0.125 mg “SAWAI” / 0.5 mg “SAWAI”

Feb. 15. 2018

Sawai Pharmaceutical receives approvals for 8 compounds with 19 strengths of generic drugs

Nov. 13. 2017

Sawai Pharmaceutical Forms Strategic Alliance with Sumitomo Corp in the US Generics Market

Jun. 01. 2017

Sawai Pharmaceutical Completes Acquisition of Upsher-Smith Laboratories’ Generics Business

Apr. 20. 2017

Japan’s Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories